Quick Answer
Chemomab Therapeutics Ltd. reported Stockholders Equity of $12.33 million for fiscal year 2025.
Chemomab Therapeutics Ltd. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $12.33M | -8.9% |
| 2024 | $13.54M | -20.4% |
| 2023 | $17.00M | -53.1% |
| 2022 | $36.22M | -41.1% |
| 2021 | $61.47M | +469.0% |
| 2020 | $10.80M | -12.7% |
| 2019 | $12.37M | +26.2% |
| 2018 | $9.80M | +1710.0% |
| 2017 | -$609.0K | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| March 31, 2023 | $27.95M | -51.2% | -22.8% |
| December 31, 2022 | $36.22M | -41.1% | -18.8% |
| September 30, 2022 | $44.62M | -31.9% | -13.9% |
| June 30, 2022 | $51.84M | -23.8% | -9.4% |
| March 31, 2022 | $57.24M | +3.8% | -6.9% |
| December 31, 2021 | $61.47M | +469.0% | -6.2% |
| September 30, 2021 | $65.51M | +438.9% | -3.7% |
| June 30, 2021 | $68.04M | +431.7% | +23.3% |
- Chemomab Therapeutics Ltd. showed a decrease of -8.9% in Stockholders Equity compared to the prior fiscal year.
- Over the 2017–2025 period, Chemomab Therapeutics Ltd.’s stockholders equity has grown by 2125.3% (from -$609.0 thousand to $12.33 million).
- The most recent figure is from Chemomab Therapeutics Ltd.’s fiscal year 2025 report (Form 20-F), filed with the SEC on March 23, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: